export type PseoContentBlock = {
  heading: string;
  body: string;
};

export type PseoFaq = {
  question: string;
  answer: string;
};

export type PseoScore = {
  label: string;
  value: number;
  note: string;
};

export type PseoContentRecord = {
  path: string;
  summary: string;
  keyPoints: string[];
  blocks: PseoContentBlock[];
  scorecard?: PseoScore[];
  decisionChecklist?: string[];
  faqs?: PseoFaq[];
};

export const pseoContentRecords: Record<string, PseoContentRecord> = {
  "/compare/bpc-157-vs-tb-500": {
    path: "/compare/bpc-157-vs-tb-500",
    summary:
      "BPC-157 excels at localized tendon, ligament, and gut healing. TB-500 is better for systemic muscle recovery and widespread inflammation.",
    keyPoints: [
      "BPC-157 is usually framed as the more localized compound in tendon, ligament, joint, and gut-repair conversations.",
      "TB-500 is usually framed as the more systemic recovery peptide for muscle repair and broader inflammation support.",
      "A useful comparison is not about hype or stacking by default. It is about whether the recovery need is local, systemic, or both.",
    ],
    scorecard: [
      { label: "Evidence", value: 5, note: "Strong preclinical interest, limited human certainty" },
      { label: "Goal fit", value: 8, note: "Very relevant for injury and recovery users" },
      { label: "Complexity", value: 7, note: "Injection handling and sourcing still matter" },
      { label: "Caution", value: 8, note: "Research-compound context should stay front and center" },
    ],
    blocks: [
      {
        heading: "BPC-157 Deep Dive",
        body:
          "BPC-157 is typically discussed as the more localized healing peptide in the pair. It shows up in tendon, ligament, joint, and gut-repair conversations because the research narrative centers on tissue repair, angiogenesis, and localized recovery support rather than broad systemic recovery alone.",
      },
      {
        heading: "TB-500 Deep Dive",
        body:
          "TB-500 is usually positioned as the more systemic recovery peptide. In practical peptide conversations, it is often described as the better fit for widespread muscle recovery, movement-related inflammation, and broader tissue-repair support beyond one localized area.",
      },
      {
        heading: "How to choose",
        body:
          "This comparison is most useful when someone is deciding between a local soft-tissue healing narrative and a more systemic recovery narrative. If the issue is specific and localized, BPC-157 usually gets more attention. If the issue is broader or more inflammation-heavy, TB-500 usually gets the nod.",
      },
    ],
    decisionChecklist: [
      "Clarify whether the problem is localized tendon, ligament, joint, or gut healing versus broader systemic recovery.",
      "Do not assume stacking is better before deciding whether one compound already fits the use case.",
      "Treat both compounds as research-context decisions, not settled clinical care.",
      "Use clinician judgment for structural injuries, persistent pain, or complex recovery situations.",
    ],
    faqs: [
      {
        question: "Is BPC-157 better than TB-500?",
        answer:
          "Not across the board. BPC-157 is usually treated as the better localized option, while TB-500 is usually treated as the better systemic option.",
      },
      {
        question: "Why do people compare BPC-157 and TB-500 so often?",
        answer:
          "Because they are often discussed together in injury-recovery circles, with BPC-157 framed as more localized and TB-500 framed as more systemic.",
      },
    ],
  },
  "/compare/semaglutide-vs-tirzepatide": {
    path: "/compare/semaglutide-vs-tirzepatide",
    summary:
      "Tirzepatide produces greater average weight loss in clinical trials. Semaglutide has a longer post-market safety record. Both are excellent options.",
    keyPoints: [
      "Semaglutide is a GLP-1 receptor agonist, while tirzepatide targets both GIP and GLP-1 receptors.",
      "Tirzepatide is often discussed for stronger average weight-loss outcomes, but tolerability, access, and supervision still matter more than headline numbers alone.",
      "A responsible comparison looks at screening, dose escalation, contraindications, and follow-up support, not just before-and-after stories.",
    ],
    scorecard: [
      { label: "Evidence", value: 9, note: "Strong clinical use and outcome data" },
      { label: "Goal fit", value: 9, note: "Highly relevant for metabolic and weight-loss research" },
      { label: "Complexity", value: 6, note: "Requires screening, titration, and follow-up" },
      { label: "Caution", value: 7, note: "Important contraindication and side-effect review" },
    ],
    blocks: [
      {
        heading: "Mechanism difference",
        body:
          "Semaglutide works through GLP-1 signaling. Tirzepatide adds GIP receptor activity on top of GLP-1 activity, which is one reason it is often discussed as a distinct option rather than just a newer version of semaglutide.",
      },
      {
        heading: "Who asks this question",
        body:
          "People usually compare semaglutide and tirzepatide when they want appetite control, weight reduction, improved metabolic markers, or a change after plateauing on another plan. The right answer depends on clinician screening, cost, insurance, history of side effects, and whether someone is treating diabetes, obesity, or another metabolic condition.",
      },
      {
        heading: "What a good provider should explain",
        body:
          "A strong clinical program should explain dose escalation, expected gastrointestinal side effects, red-flag symptoms, medication sourcing, refill timing, and when a patient should stop and contact a clinician. Those practical details matter as much as the medication name.",
      },
    ],
    decisionChecklist: [
      "Clarify whether you are comparing branded prescriptions, compounded care, or unsafe gray-market sourcing.",
      "Ask how dose titration is handled and what happens if side effects appear.",
      "Verify who reviews contraindications such as pancreatitis history, gallbladder disease, or complex medication interactions.",
      "Compare the total monthly cost, not just the teaser price.",
    ],
    faqs: [
      {
        question: "Is tirzepatide always better than semaglutide?",
        answer:
          "Not automatically. Average outcome data can look stronger in some contexts, but real-world fit depends on side effects, access, cost, clinician support, and the user's health history.",
      },
      {
        question: "Are these research peptides?",
        answer:
          "No. These are clinically used metabolic medications and should not be framed the same way as gray-market research compounds.",
      },
    ],
  },
  "/goals/fat-loss": {
    path: "/goals/fat-loss",
    summary:
      "Evidence-based rankings for sustainable fat loss, metabolic health, and body recomposition.",
    keyPoints: [
      "GLP-1 and dual incretin therapies are the most clinically established category for appetite and weight management.",
      "Research compounds like MOTS-c or AOD-9604 are discussed differently from prescription metabolic drugs and should be framed accordingly.",
      "Sustainable fat loss still depends on nutrition, resistance training, sleep, and medical screening.",
    ],
    scorecard: [
      { label: "Evidence", value: 8, note: "Mixed by category, strongest around incretin therapies" },
      { label: "Goal fit", value: 9, note: "Very high interest and broad practical relevance" },
      { label: "Complexity", value: 7, note: "Source type and mechanism change the decision" },
      { label: "Caution", value: 7, note: "Medical context and sourcing quality matter" },
    ],
    blocks: [
      {
        heading: "Common categories",
        body:
          "Users researching fat loss usually encounter semaglutide, tirzepatide, MOTS-c, AOD-9604, Tesamorelin, and growth-hormone secretagogues. Those names live in very different evidence tiers, which means the safest next step is not simply choosing the most exciting one.",
      },
      {
        heading: "What actually changes the decision",
        body:
          "The important distinctions are whether a person needs appetite regulation, glycemic support, body-composition improvement, visceral-fat reduction, or better recovery so they can train consistently. The right framework is more specific than simply 'burn fat.'",
      },
      {
        heading: "Sourcing and supervision",
        body:
          "The biggest mistakes usually happen when people treat prescription care, compounded medication, and research-only compounds as if they are interchangeable. Provider quality, medication sourcing, injection safety, and monitoring all need to be evaluated separately.",
      },
    ],
    decisionChecklist: [
      "Decide whether you are evaluating prescription care, compounded care, or research-only compounds.",
      "Match the goal to the mechanism: appetite, glycemic control, visceral fat, or training recovery.",
      "Ask what monitoring is available if side effects or plateaus show up.",
      "Avoid any source that promises dramatic results without screening or follow-up.",
    ],
    faqs: [
      {
        question: "Are fat-loss peptides enough by themselves?",
        answer:
          "No. Even clinically established therapies work best alongside nutrition, resistance training, sleep, and medical oversight.",
      },
      {
        question: "Is every peptide discussed for fat loss medically approved?",
        answer:
          "No. Many compounds in fat-loss discussions are still research-focused or appear in gray-market conversations rather than established prescription care.",
      },
    ],
  },
  "/peptides/bpc-157": {
    path: "/peptides/bpc-157",
    summary:
      "BPC-157 is one of the most searched recovery peptides, usually discussed around tendon, ligament, joint, soft-tissue, and gut support. The interest is strong, but human evidence remains limited, which means the safety conversation has to be more careful than the marketing conversation.",
    keyPoints: [
      "Most BPC-157 discussion is based on preclinical and anecdotal evidence rather than large human trials.",
      "The most common research themes are musculoskeletal recovery and gut barrier support.",
      "Source quality, sterility, and clinical judgment matter because regulatory status is unsettled and gray-market sourcing is common.",
    ],
    scorecard: [
      { label: "Evidence", value: 4, note: "Strong interest, limited human evidence" },
      { label: "Goal fit", value: 8, note: "Frequently researched for recovery and tissue support" },
      { label: "Complexity", value: 7, note: "Handling and sourcing quality change the risk" },
      { label: "Caution", value: 8, note: "Gray-market quality issues deserve real skepticism" },
    ],
    blocks: [
      {
        heading: "Why people research it",
        body:
          "BPC-157 shows up in conversations about tendon pain, ligament strain, post-training recovery, joint irritation, and gut support. The appeal comes from preclinical studies and strong anecdotal momentum rather than the kind of large clinical evidence people might assume from how confidently it is marketed online.",
      },
      {
        heading: "Where caution belongs",
        body:
          "The main question is not whether BPC-157 sounds promising. The harder question is whether the source is sterile, whether the product is what it claims to be, and whether someone understands the limits of the evidence before considering injections or self-experimentation.",
      },
      {
        heading: "How to evaluate a provider",
        body:
          "A decent provider or vendor page should be clear about sourcing, testing, sterility expectations, and what is known versus speculative. Pages that imply clinical certainty without acknowledging evidence limits deserve more skepticism, not less.",
      },
    ],
    decisionChecklist: [
      "Separate preclinical promise from proven human benefit.",
      "Verify whether the source provides real testing and appropriate sterile handling information.",
      "Be wary of aggressive claims around injury healing timelines.",
      "Discuss injection, recovery, and orthopedic questions with a clinician when pain or structural injury is involved.",
    ],
    faqs: [
      {
        question: "Is BPC-157 approved as a standard prescription therapy?",
        answer:
          "It is not generally positioned like mainstream approved medications. That is part of why sourcing and evidence quality matter so much in this space.",
      },
      {
        question: "Why is BPC-157 so popular despite limited human data?",
        answer:
          "Because recovery stories spread quickly and people with stubborn injuries are often willing to explore compounds that sound promising before the evidence is fully mature.",
      },
    ],
  },
  "/peptides/tb-500": {
    path: "/peptides/tb-500",
    summary:
      "TB-500 is a naturally occurring peptide found in high concentrations in blood platelets and wound fluid.",
    keyPoints: [
      "TB-500 is usually discussed as a systemic recovery peptide in joint, tendon, ligament, and soft-tissue conversations.",
      "Most of the interest comes from preclinical and anecdotal evidence rather than large-scale human trials.",
      "Source quality, sterile handling, and evidence limits still matter more than the confidence of the marketing copy.",
    ],
    scorecard: [
      { label: "Evidence", value: 5, note: "Compelling preclinical story, limited human depth" },
      { label: "Goal fit", value: 8, note: "Strong research interest for recovery contexts" },
      { label: "Complexity", value: 7, note: "Injection handling and sourcing change the risk" },
      { label: "Caution", value: 8, note: "Should be viewed as a research compound, not settled care" },
    ],
    blocks: [
      {
        heading: "How TB-500 Works",
        body:
          "TB-500 is typically discussed in relation to cell migration, tissue repair, and inflammation modulation. In practical peptide conversations, it is often framed as the more systemic counterpart to compounds like BPC-157, especially when the goal is broad recovery support rather than only localized tissue focus.",
      },
      {
        heading: "Evidence Base",
        body:
          "The compound has a strong preclinical narrative around wound healing, tissue remodeling, and recovery from musculoskeletal strain. Human evidence remains limited, which means confidence should stay anchored to the actual evidence level rather than the enthusiasm of online testimonials.",
      },
      {
        heading: "Practical Use Context",
        body:
          "People researching TB-500 are usually looking at tendon issues, injury recovery, joint irritation, or heavy training recovery. The main questions should still be source quality, sterile technique, and whether a clinician should be involved before self-directed experimentation is even considered.",
      },
    ],
    decisionChecklist: [
      "Separate the strong preclinical recovery narrative from mature human clinical certainty.",
      "Verify whether the source explains testing, sterility, and handling clearly.",
      "Be skeptical of any page that implies guaranteed healing timelines.",
      "Use medical judgment for serious injuries, persistent pain, or structural issues.",
    ],
    faqs: [
      {
        question: "Is TB-500 the same as Thymosin Beta-4?",
        answer:
          "TB-500 is commonly described as a synthetic fragment or analog associated with Thymosin Beta-4 discussion. In practical peptide research conversations, the two are often mentioned together even though the naming is not always handled carefully online.",
      },
      {
        question: "Why is TB-500 often paired with BPC-157?",
        answer:
          "Usually because TB-500 is framed as the more systemic recovery peptide while BPC-157 is framed as more localized. That pairing logic is common, though it still does not remove the need for evidence awareness and sourcing caution.",
      },
    ],
  },
  "/guides/how-to-reconstitute-peptides": {
    path: "/guides/how-to-reconstitute-peptides",
    summary:
      "Step-by-step guide to reconstituting lyophilized peptides safely. Bacteriostatic water, dosing calculations, storage, and common mistakes. Beginner-friendly.",
    keyPoints: [
      "Use sterile supplies and avoid touching sterile surfaces.",
      "Confirm the vial amount, diluent volume, and intended concentration before mixing anything.",
      "Do not use cloudy, contaminated, expired, or questionable material.",
    ],
    scorecard: [
      { label: "Clarity", value: 9, note: "Core concepts are teachable and repeatable" },
      { label: "Practical value", value: 9, note: "High-value page for real user mistakes" },
      { label: "Complexity", value: 8, note: "Math and sterile handling both matter" },
      { label: "Caution", value: 9, note: "Dosing and contamination mistakes can snowball fast" },
    ],
    blocks: [
      {
        heading: "Core concept",
        body:
          "Reconstitution changes a dry vial into a liquid concentration that can be measured. Dose volume depends on both how much peptide is in the vial and how much diluent was added. People get into trouble when they copy someone else's injection volume without matching the same concentration.",
      },
      {
        heading: "Common error pattern",
        body:
          "The most common mistakes are using the wrong vial strength, misreading syringe units, reusing supplies incorrectly, or assuming every peptide is reconstituted the same way. Those are practical errors, not theoretical ones, and they can change dosing dramatically.",
      },
      {
        heading: "When to stop",
        body:
          "If the vial looks contaminated, the storage history is unclear, or the math does not make sense, stop and re-check everything. Uncertainty is a reason to pause, not a reason to guess.",
      },
    ],
    decisionChecklist: [
      "Write down the vial strength and planned diluent volume before mixing.",
      "Check whether the resulting concentration matches the dose you think you are taking.",
      "Use clean technique and do not touch sterile surfaces.",
      "Do not rely on screenshot math from strangers if your vial size or dilution volume differs.",
    ],
    faqs: [
      {
        question: "Why do people mis-dose peptides after reconstitution?",
        answer:
          "Usually because they copy syringe-unit instructions from another person without matching the same vial size, diluent volume, or target concentration.",
      },
      {
        question: "Does every peptide use the same reconstitution approach?",
        answer:
          "No. The math and handling depend on the vial strength, the intended concentration, the diluent used, and the route of administration under clinician guidance.",
      },
    ],
  },
  "/stacks/recovery-stack": {
    path: "/stacks/recovery-stack",
    summary:
      "The most researched peptide combination for injury healing, joint recovery, and tissue repair.",
    keyPoints: [
      "BPC-157 and TB-500 are often paired because people want both local tissue support and broader recovery signaling.",
      "Most of the enthusiasm around this stack comes from preclinical logic and anecdotal reports, not large human trials.",
      "The real risks are sourcing quality, sterile handling, unrealistic expectations, and using a stack when a clinician should be evaluating a structural injury.",
    ],
    scorecard: [
      { label: "Recovery fit", value: 9, note: "Frequently researched for injuries and soft-tissue repair" },
      { label: "Evidence", value: 4, note: "Strong interest, limited human clinical depth" },
      { label: "Complexity", value: 8, note: "Stacking, sourcing, and injections add friction" },
      { label: "Caution", value: 8, note: "Do not confuse online enthusiasm with proven medical certainty" },
    ],
    blocks: [
      {
        heading: "Why these peptides are stacked together",
        body:
          "People pair BPC-157 with TB-500 because the compounds are usually framed as complementary rather than redundant. BPC-157 is often discussed for tendon, ligament, joint, and gut-support contexts, while TB-500 is usually described as the more systemic recovery peptide in the pair.",
      },
      {
        heading: "What a realistic protocol conversation looks like",
        body:
          "A serious provider or educational page should talk about injury type, whether the issue is acute or chronic, what supporting rehab is happening, and what outcome would count as progress. A stack should not be presented as a shortcut that replaces imaging, physical therapy, or orthopedic evaluation when those are needed.",
      },
      {
        heading: "Where caution belongs",
        body:
          "The most common mistakes are stacking too quickly, assuming more compounds means faster healing, copying internet injection plans, or buying from weak gray-market sources. The stack can sound elegant on paper while still being poorly executed in real life.",
      },
    ],
    decisionChecklist: [
      "Clarify whether the goal is tendon recovery, joint irritation, post-surgical healing, or generalized recovery support.",
      "Do not use stacking as a substitute for clinical evaluation of a serious injury.",
      "Verify sterility, source quality, and handling practices before anyone thinks about injections.",
      "Track progress against pain, function, range of motion, and training capacity rather than hype alone.",
    ],
    faqs: [
      {
        question: "Why do people combine BPC-157 and TB-500?",
        answer:
          "Usually because they want the perceived local-repair benefits of BPC-157 alongside the more systemic recovery narrative around TB-500.",
      },
      {
        question: "Does stacking automatically mean better results?",
        answer:
          "No. More compounds do not guarantee a better outcome, and stacking can increase cost, complexity, and sourcing risk without solving the underlying problem.",
      },
    ],
  },
  "/reviews/bpc-157-review": {
    path: "/reviews/bpc-157-review",
    summary:
      "BPC-157 is the most researched healing peptide available, with an impressive preclinical evidence base across multiple organ systems. Its safety profile is excellent and user satisfaction is high. The primary limitation is the lack of large-scale human clinical trials.",
    keyPoints: [
      "BPC-157 has broad preclinical momentum in tendon, ligament, muscle, and gut-related discussions.",
      "The largest weakness is still the lack of robust, large-scale human clinical evidence.",
      "A serious review should talk as much about sourcing and evidence limits as about upside.",
    ],
    scorecard: [
      { label: "Evidence quality", value: 7, note: "Excellent preclinical depth, limited human proof" },
      { label: "Safety profile", value: 8, note: "Anecdotally favorable, but human certainty remains incomplete" },
      { label: "Value for money", value: 7, note: "Can be compelling if the recovery use case is well chosen" },
      { label: "Ease of use", value: 6, note: "Handling, sourcing, and injection comfort matter" },
    ],
    blocks: [
      {
        heading: "What stands out",
        body:
          "BPC-157 has one of the most developed recovery narratives in the peptide world. That is not just marketing momentum; there is a real base of preclinical interest across tendon, ligament, soft tissue, and gut-related research themes.",
      },
      {
        heading: "What keeps the review from going higher",
        body:
          "The biggest drag on any honest BPC-157 rating is the same thing every time: strong mechanistic and preclinical interest is not the same as mature human clinical proof. People should know that before they treat the compound like settled medicine.",
      },
      {
        heading: "Who tends to research it",
        body:
          "BPC-157 usually attracts athletes with stubborn connective-tissue issues, people dealing with recurring joint irritation, and users interested in gut-support discussions. The fit question matters more than the hype question.",
      },
    ],
    decisionChecklist: [
      "Separate preclinical enthusiasm from proven clinical certainty.",
      "Ask whether the source is trusted enough to justify the experiment at all.",
      "Be skeptical of any review that never mentions evidence limits or sourcing quality.",
      "Avoid using a review as permission to self-manage a serious injury without medical input.",
    ],
    faqs: [
      {
        question: "Is BPC-157 worth it for everyone with an injury?",
        answer:
          "No. The right question is whether the recovery context, evidence tolerance, and sourcing quality justify it for that person, not whether it sounds exciting in general.",
      },
      {
        question: "Why do so many BPC-157 reviews sound overly certain?",
        answer:
          "Because the compound has strong anecdotal momentum and commercial interest, which often makes the human-evidence caveats feel quieter than they should be.",
      },
    ],
  },
  "/reviews/semaglutide-review": {
    path: "/reviews/semaglutide-review",
    summary:
      "Semaglutide is a clinically established GLP-1 medication used in diabetes and weight-management care, but the experience someone gets still depends heavily on the provider, medication sourcing, screening, side-effect support, and pricing clarity. A real review should focus on the care model, not just the molecule.",
    keyPoints: [
      "Semaglutide has substantial clinical evidence for metabolic outcomes.",
      "The biggest review questions are provider quality, sourcing transparency, and side-effect support.",
      "A serious review separates branded prescription care, compounded care, and unsafe or unverifiable sourcing.",
    ],
    scorecard: [
      { label: "Evidence", value: 9, note: "Substantial clinical backing in metabolic care" },
      { label: "Provider fit", value: 8, note: "Program quality changes the real experience" },
      { label: "Complexity", value: 6, note: "Straightforward concept, but not plug-and-play" },
      { label: "Caution", value: 7, note: "Screening and sourcing still need scrutiny" },
    ],
    blocks: [
      {
        heading: "What semaglutide does",
        body:
          "Semaglutide mimics GLP-1 signaling, which can affect appetite, satiety, gastric emptying, and glucose regulation. That is why it belongs in a medication-and-provider review context rather than a generic peptide hype context.",
      },
      {
        heading: "How to review a provider",
        body:
          "A good semaglutide program should explain screening, refill reliability, dose escalation, side-effect protocols, medication sourcing, clinician access, and total cost. Reviews that focus only on convenience or dramatic outcomes miss the actual operating risks.",
      },
      {
        heading: "What to be skeptical of",
        body:
          "Be careful with offers that hide refill pricing, imply that everyone qualifies, skip meaningful screening, or blur the difference between licensed care and loosely sourced products. The care model matters as much as the product name.",
      },
    ],
    decisionChecklist: [
      "Verify who is prescribing and what screening happens before treatment.",
      "Ask whether the medication is branded, compounded, or sourced another way.",
      "Check how side effects, refills, and follow-up questions are handled.",
      "Compare the full ongoing monthly cost, not just the first-month headline.",
    ],
    faqs: [
      {
        question: "Is semaglutide the same kind of thing as a research peptide?",
        answer:
          "No. It belongs in the category of clinically used metabolic medication and should be evaluated through a medical-care lens.",
      },
      {
        question: "What makes one semaglutide provider better than another?",
        answer:
          "Screening quality, sourcing transparency, follow-up access, side-effect support, and pricing clarity are usually the deciding factors.",
      },
    ],
  },
};

export function getPseoContent(path: string) {
  return pseoContentRecords[path];
}
